Recovery and functional activity of mononuclear bone marrow and peripheral blood cells after different cell isolation protocols used in clinical trials for cell therapy after acute myocardial infarction

2008 ◽  
Vol 4 (1) ◽  
pp. 133-138 ◽  
Author(s):  
Rachel van Beem ◽  
Alexander Hirsch ◽  
Ingrid Lommerse ◽  
Jaap Zwaginga ◽  
Willy Noort ◽  
...  
Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Mahan Shahrivari ◽  
Elizabeth Wise ◽  
Doris A Taylor ◽  
Carl J Pepine ◽  
Timothy D Henry ◽  
...  

Background: Intracoronary infusion of bone marrow (BM) mononuclear cells (BM-MNCs) late after acute myocardial infarction (AMI) has shown no improvement in global or regional left ventricular (LV) function (LateTIME and SWISS-AMI). Studies in experimental AMI models suggest a possible cytokine-related depression of progenitor cell function. Furthermore, BM cell content is correlated with the LV functional response. Accordingly, we hypothesize that inflammatory cytokines associated with the late phase of AMI may impair BM function and alter progenitor cell subsets. Method: Patients with previous AMI (n=87) were recruited in a multicenter cell therapy trial by the Cardiovascular Cell Therapy Research Network (CCTRN LateTIME, NCT00684060). BM and peripheral blood (PB) were collected 2-3 weeks after AMI and examined for cell phenotypes and progenitor capacities as well as PB inflammatory and angiogenic cytokines in a core laboratory. Multiple regression analyses were conducted and correlations between cytokine levels and cell phenotypes, cell functions, and post-MI cardiac function were determined. BM from healthy donors, handled in the same manner, was used as a reference. Result: Of 26 cytokines analyzed, IL-6 showed a negative correlation with ECFC colony maximum in BM (estimate±SE (SEE) -0.13±0.04 P=0.007, multivariableR2: 0.59) and Healthy BM showed decreased ECFC colony outgrowth in the presence of IL-6 (P <0.05), in a dose-dependent manner. PDGF-BB positively correlated with CFU-EC colony maximum in BM (SEE 0.006± 0.002, P=0.023, R2: 0.22), MSC colony maximum in BM (SEE 0.006±0.002, P=0.023, R2: 0.17) and MSC colony maximum in PB (SSE 0.018±0.005, P=0.00005, R2:0.24). No significant correlations were found between cardiac function after AMI and PB cytokine levels. Conclusions: At 2-3 weeks after AMI, PB levels of the angiogenic cytokine, PDGF-BB and the pro-inflammatory cytokine, IL-6, were associated with BM cell phenotype and function. IL-6 has the potential to impair endothelial progenitor cell capacity; inhibiting IL-6 may be a target for improving the regenerative capacity of BM cells after AMI.


2012 ◽  
Vol 5 (3) ◽  
pp. 309-320 ◽  
Author(s):  
Tiago Carvalheiro ◽  
Isabel Velada ◽  
Ana Valado ◽  
Fernando Mendes ◽  
António Martinho ◽  
...  

2010 ◽  
Vol 104 (07) ◽  
pp. 6-12 ◽  
Author(s):  
Chung-Wah Siu ◽  
Song-Yan Liao ◽  
Yuan Liu ◽  
Qizhou Lian ◽  
Hung-Fat Tse

SummaryThere is a growing interest in the clinical application for stem cell as a novel therapy for treatment of acute myocardial infarction and chronic myocardial ischaemia. The initial premise is the transplanted exogenous stem cells can engraft and integrate with host myocardium for cardiac regeneration. However, recent experimental studies suggest that multiple mechanisms, including remodelling of extracellular matrix, enhancement of neovascularisation and recruitment of endogenous stem cells are more likely to contribute to the beneficial effects of stem cell therapy that direct trans-differentiation of stem cells into functional myocardium. Among different potential cell sources, bone marrow-derived cells and skeletal myoblasts have been tested in pilot clinical trials. Phase I/II randomised controlled clinical trials suggest that intracoronary or intramyocardial injection of bone marrow-derived cells may be safe and feasible strategies for treatment of acute myocardial infarction as well as chronic myocardial ischaemia. In addition, these studies show a modest, but significant improvement in left ventricular ejection fraction and clinical status of patients after cell transplantation. Nevertheless, most of these studies included a relatively small sample size (<200) and short duration of follow-up (<6 months), and the clinical efficacy of stem cell therapy need to be confirmed by future clinical trials. Furthermore, the optimal timing, cell types and mode of delivery need to be addressed, and strategies to improve cell survival and engraftment should also be developed to overcome the potential hurdles related to cell-based therapy.


Heart ◽  
2014 ◽  
Vol 101 (5) ◽  
pp. 363-368 ◽  
Author(s):  
Ronak Delewi ◽  
Anja M van der Laan ◽  
Lourens F H J Robbers ◽  
Alexander Hirsch ◽  
Robin Nijveldt ◽  
...  

2001 ◽  
Vol 344 (3) ◽  
pp. 175-181 ◽  
Author(s):  
William I. Bensinger ◽  
Paul J. Martin ◽  
Barry Storer ◽  
Reginald Clift ◽  
Steven J. Forman ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document